Almirall Drops on U.S. Regulator’s Scrutiny of Lung Drug
This article is for subscribers only.
Almirall SA dropped the most in more than two months after the Spanish drugmaker said it must hold an additional meeting with U.S. regulators before seeking approval to sell a new treatment for a lung disorder.
Almirall fell 5.8 percent to 11.15 euros in Madrid, the steepest decline since Jan. 23. That pushed the stock into losses for the year, cutting the pharmaceutical producer’s value to 1.93 billion euros ($2.67 billion).